{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T19:17:51Z","timestamp":1770664671504,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"vor","delay-in-days":310,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ijbiomac.2022.06.195","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T18:58:27Z","timestamp":1657133907000},"page":"465-474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["An effective strategy for the humanization of antibody fragments under an accelerated timeline"],"prefix":"10.1016","volume":"216","author":[{"given":"Isabella Gizzi","family":"Jiacomini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Beltramino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Boursin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Carlos","family":"Minozzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana Ferreira","family":"de Moura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Billiald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa Magalh\u00e3es","family":"Alvarenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Aubrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0005","series-title":"Omics Technologies and Bio Engineering","first-page":"449","article-title":"Chapter 19 \u2013 medical biotechnology: techniques and applications","author":"Pham","year":"2018"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0010","series-title":"Drugs@FDA","year":"2021"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0015","doi-asserted-by":"crossref","unstructured":"S. Singh N.K. Tank P. Dwiwedi J. Charan R. Kaur P. Sidhu V.K. Chugh Monoclonal Antibodies: A Review, Current Clinical Pharmacology. 13 (n.d.) 85\u201399. https:\/\/www.eurekaselect.net\/article\/85198 (accessed December 30, 2021).","DOI":"10.2174\/1574884712666170809124728"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0025","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/aps.2010.120","article-title":"Research, and development of next generation of antibody-based therapeutics","volume":"31","author":"Li","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/antib6030012","article-title":"Functional, biophysical, and structural characterization of human IgG1 and IgG4 fc variants with ablated immune functionality","volume":"6","author":"Tam","year":"2017","journal-title":"Antibodies"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/antib4030259","article-title":"Antibody fragments and their purification by protein L affinity chromatography","volume":"4","author":"Rodrigo","year":"2015","journal-title":"Antibodies"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0040","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/19420862.2017.1336592","article-title":"Design, development, and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks","volume":"9","author":"Lebozec","year":"2017","journal-title":"MAbs"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0045","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-8958-4_10","article-title":"Antibody fragments humanization: beginning with the end in mind","author":"Aubrey","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0050","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1073\/pnas.1616408114","article-title":"Biophysical properties of the clinical-stage antibody landscape","volume":"114","author":"Jain","year":"2017","journal-title":"PNAS"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0055","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.toxicon.2003.09.006","article-title":"Production of monoclonal antibodies capable of neutralizing dermonecrotic activity of Loxosceles intermedia spider venom and their use in a specific immunometric assay","volume":"42","author":"Alvarenga","year":"2003","journal-title":"Toxicon"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0060","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.imlet.2016.05.019","article-title":"Generation of recombinant antibody fragments with toxin-neutralizing potential in loxoscelism","volume":"176","author":"Karim-Silva","year":"2016","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2016.03.001","article-title":"Immunodetection of the \u201cbrown\u201d spider (Loxosceles intermedia) dermonecrotoxin with an scFv-alkaline phosphatase fusion protein","volume":"173","author":"Jiacomini","year":"2016","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0070","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/toxins12040256","article-title":"Loxoscelism: advances and challenges in the design of antibody fragments with therapeutic potential","volume":"12","author":"Karim-Silva","year":"2020","journal-title":"Toxins"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/02648725.2013.801235","article-title":"Antibody humanization methods \u2013 a review and update","volume":"29","author":"Safdari","year":"2013","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0080","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/19420862.2015.1116657","article-title":"A method to confer protein L binding ability to any antibody fragment","volume":"8","author":"Lakhrif","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0085","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0090","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/msb.2011.75","article-title":"Fast, scalable generation of high-quality protein multiple sequence alignments using clustal omega","volume":"7","author":"Sievers","year":"2011","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0095","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1073\/pnas.77.7.4216","article-title":"Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity","volume":"77","author":"Urlaub","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0100","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jps.23405","article-title":"High-throughput melting-temperature analysis of a monoclonal antibody by differential scanning fluorimetry in the presence of surfactants","volume":"102","author":"Menzen","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0105","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1093\/bioinformatics\/15.12.1020","article-title":"Browsing protein families via the \u201crich family description\u201d format","volume":"15","author":"Corpet","year":"1999","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0110","series-title":"Comparative Protein Structure Modeling Using Modeller. Current Protocols in Bioinformatics","first-page":"5.6.1","volume":"54","author":"Webb","year":"2016"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0115","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1080\/19420862.2016.1205773","article-title":"ABodyBuilder: automated antibody structure prediction with data\u2013driven accuracy estimation","volume":"8","author":"Leem","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0120","series-title":"The NCBI Handbook [Internet]","article-title":"The BLAST Sequence Analysis Tool. 2002 Oct 9 [Updated 2003 Aug 13]","author":"Madden","year":"2002"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0125","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0130","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/tan.12956","article-title":"Common and well-documented HLA alleles over all of Europe and within European sub-regions: a catalogue from the European Federation for Immunogenetics","volume":"89","author":"Sanchez-Mazas","year":"2017","journal-title":"HLA"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.00703","article-title":"Cost of manufacturing for recombinant snakebite antivenoms","volume":"8","author":"Jenkins","year":"2020","journal-title":"Front.Bioeng.Biotechnol."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0140","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.molimm.2006.05.009","article-title":"The change of the scFv into the Fab format improves the stability and in vivo toxin neutralization capacity of recombinant antibodies","volume":"44","author":"Quintero-Hern\u00e1ndez","year":"2007","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0145","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jim.2018.10.012","article-title":"Unravelling enhancement of antibody fragment stability \u2013 role of format structure and cysteine modification","volume":"464","author":"Ma","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0150","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1007\/s00253-016-7388-9","article-title":"Advances in recombinant antibody manufacturing","volume":"100","author":"Kunert","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0155","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3389\/fimmu.2017.01287","article-title":"Antibody or antibody fragments: implications for molecular imaging and targeted therapy of solid tumors","volume":"8","author":"Xenaki","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0160","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/j.1742-4658.2006.05232.x","article-title":"The role of interface framework residues in determining antibody VH\/VL interaction strength and antigen-binding affinity","volume":"273","author":"Masuda","year":"2006","journal-title":"FEBS J."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0165","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1038\/s41598-017-02756-3","article-title":"The role of antibody V\u03ba framework 3 region towards antigen binding: effects on recombinant production and protein L binding","volume":"7","author":"Su","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.630034","article-title":"Mutation of framework residue H71 results in different antibody paratope states in solution","volume":"12","author":"Fern\u00e1ndez-Quintero","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/antib9020009","article-title":"Exploration and modulation of antibody fragment biophysical properties by replacing the framework region sequences","volume":"9","author":"Cnudde","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0180","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.4049\/jimmunol.165.8.4505","article-title":"Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody","volume":"165","author":"Winkler","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0185","doi-asserted-by":"crossref","first-page":"W125","DOI":"10.1093\/nar\/gkaa389","article-title":"mmCSM-AB: guiding rational antibody engineering through multiple point mutations","volume":"48","author":"Myung","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0190","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1472-6750-13-55","article-title":"Monoclonal antibody humanness score and its applications","volume":"13","author":"Gao","year":"2013","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0195","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0200","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/btpr.1767","article-title":"Free light chain content in culture media reflects recombinant monoclonal antibody productivity and quality","volume":"29","author":"Bhoskar","year":"2013","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0205","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1021\/bp049780w","article-title":"On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells","volume":"21","author":"Schlatter","year":"2005","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0210","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.4161\/mabs.29680","article-title":"A general approach to antibody thermostabilization","volume":"6","author":"McConnell","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0215","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.biochi.2020.08.019","article-title":"Antibody stability: a key to performance \u2013 analysis, influences, and improvement","volume":"177","author":"Ma","year":"2020","journal-title":"Biochimie"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00217","article-title":"Expression of recombinant antibodies","volume":"4","author":"Frenzel","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0225","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jpba.2017.12.022","article-title":"Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol","volume":"150","author":"Mohamed","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0230","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/19420862.2015.1112477","article-title":"Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab","volume":"8","author":"Courtois","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0235","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0240","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.bbapap.2014.08.003","article-title":"pH-dependent antigen-binding antibodies as a novel therapeutic modality","volume":"1844","author":"Igawa","year":"2014","journal-title":"Biochim. Biophys. Acta (BBA) \u2013 Proteins Proteomics"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0245","first-page":"897","article-title":"Modelling of pH-dependence to develop a strategy for abelling mAbs at acidic steps in production","volume":"18","author":"Hebditch","year":"2020","journal-title":"computational and structuralBiotechnol. J."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0250","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bit.27237","article-title":"Understanding mAb aggregation during low pH viral inactivation and subsequent neutralization","volume":"117","author":"W\u00e4lchli","year":"2020","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0255","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1110\/ps.073156708","article-title":"Critical contribution of VH\u2013VL interaction to reshaping of an antibody: the case of humanization of anti-lysozyme antibody, HyHEL-10","volume":"17","author":"Nakanishi","year":"2008","journal-title":"Protein Sci."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0260","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.imbio.2011.07.004","article-title":"A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates","volume":"216","author":"Fern\u00e1ndez-Marrero","year":"2011","journal-title":"Immunobiology"},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0265","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/protein\/gzaa004","article-title":"Antibody humanization\u2014the influence of the antibody framework on the CDR-H3 loop ensemble in solution","volume":"32","author":"Fern\u00e1ndez-Quintero","year":"2019","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.ijbiomac.2022.06.195_bb0270","doi-asserted-by":"crossref","DOI":"10.1590\/1678-9199-jvatitd-2019-0099","article-title":"Recombinant antibodies against Iranian cobra venom as a new emerging therapy by phage display technology","volume":"26","author":"Nazari","year":"2020","journal-title":"J. Venom. Anim. Toxins Incl. Trop. Dis."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813022014088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813022014088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T09:40:11Z","timestamp":1758879611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813022014088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":54,"alternative-id":["S0141813022014088"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.06.195","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An effective strategy for the humanization of antibody fragments under an accelerated timeline","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.06.195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V.","name":"copyright","label":"Copyright"}]}}